Daniel S Shin

Michael E. DeBakey VA Medical Center, Houston, TX

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

6 more share only the name and are not shown

Trial papers

PubMed author-name match

Trials

Studies that name Daniel S Shin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:57 UTC. Open this list on ClinicalTrials.gov

Ph1/Ph2
NCT05467748 · EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
VA Office of Research and Development · recruiting · Non Small Cell Lung Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
I01CX002499 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · fiscal years 2023 to 2026
Same name and institution; not confirmed by an ID

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:57 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed

PD-1 Blockade Expands Intratumoral Memory T Cells.
Cancer Immunol Res · 2016
336 citations
RCR 9.2
Biochemical and structural analysis of the IgE binding sites on ara h1, an abundant and highly allergenic peanut protein.
J Biol Chem · 1998
175 citations
RCR 5.2
Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
J Nucl Med · 2009
88 citations
RCR 3.2
A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes.
Cancer · 2020
53 citations
RCR 3.0
Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.
Vasc Med · 2010
52 citations
RCR 1.6
Computer-assisted, interactive fundus image processing for macular drusen quantitation.
Ophthalmology · 1999
50 citations
RCR 2.2
Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group.
Ophthalmology · 1999
43 citations
RCR 1.7
Machine Learning-based Individual Assessment of Cortical Atrophy Pattern in Alzheimer's Disease Spectrum: Development of the Classifier and Longitudinal Evaluation.
Sci Rep · 2018
42 citations
RCR 2.1
Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
J Clin Pharm Ther · 2014
11 citations
RCR 0.6
Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism.
Drug Des Devel Ther · 2017
9 citations
RCR 0.4